N-Acetyl-p-benzoquinone Imine, the Toxic Metabolite of Acetaminophen, Is a Topoisomerase II Poison

Biochemistry

Volumn 43, Issue 12, 2004, Pages 3731-3739

  Bender, Ryan P ^a   Lindsey Jr , R Hunter ^a   Burden, D Andrew ^b   Osheroff, Neil ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MIDDLE TENNESSEE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATALYST POISONING; CELLS; DNA; DRUG PRODUCTS; ENZYMES; TUMORS;

ANALGESICS; POISONS;

METABOLITES;

ANALGESIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DRUG METABOLITE; ETOPOSIDE; N ACETYL 4 BENZOQUINONE IMINE; PARACETAMOL; PARACETAMOL DERIVATIVE; POISON; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; DNA CLEAVAGE; DRUG MECHANISM; DRUG OVERDOSE; ENZYME ACTIVITY; GENOTOXICITY; LEUKEMIA CELL; LIVER TOXICITY; PRIORITY JOURNAL;

ACETAMINOPHEN; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BENZOQUINONES; CELL LINE, TUMOR; CHROMOSOME BREAKAGE; DNA DAMAGE; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; ETOPOSIDE; HUMANS; IMINES; MUTAGENS;

EID: 1642379266     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi036107r     Document Type: Article

References (81)

1. Prescott, L. F. (2000) Paracetamol: past, present, and future, Am. J. Ther. 7, 143-147.
2. Farrell, S. E. (2003) Toxicity, Acetaminophen, eMedicine, http://www.emedicine.com/emerg/topic819.htm.
3. Gyamlani, G. G., and Parikh, C. R. (2002) Acetaminophen toxicity: suicidal vs accidental, Crit. Care 6, 155-159.
4. Litovitz, T. L., Klein-Schwartz, W., Rodgers, G. C., Jr., Cobaugh, D. J., Youniss, J., Omslaer, J. C., May, M. E., Woolf, A. D., and Benson, B. E. (2002) 2001 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System, Am. J. Emerg. Med. 20, 391-452.
5. Beers, M. H., and Berkow, R. (2003) in The Merck Manual of Diagnosis and Therapy, pp 1676-1677, Merck & Co., Whitehouse Station, NJ.
6. Prescott, L. F. (1996) in Paracetamol (Acetaminophen). a Critical Bibliographic Review (Prescott, L. F., Ed.) pp 67-102, Taylor and Francis, Ltd., London.
7. Bessems, J. G., and Vermeulen, N. P. (2001) Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches, Crit. Rev. Toxicol. 31, 55-138.
8. Ruepp, S. U., Tonge, R. P., Shaw, J., Wallis, N., and Pognan, F. (2002) Genomics and proteomics analysis of acetaminophen toxicity in mouse liver, Toxicol. Sci. 65, 135-150.
9. Dargan, P. I., and Jones, A. L. (2003) Management of paracetamol poisoning, Trends Pharmacol. Sci. 24, 154-157.
10. Guengerich, F. P., and Liebler, D. C. (1985) Enzymatic activation of chemicals to toxic metabolites, Crit. Rev. Toxicol. 14, 259-307.
11. Riordan, S. M., and Williams, R. (2002) Alcohol exposure and paracetamol-induced hepatotoxicity, Addict. Biol. 7, 191-206.
12. Zhang, J., Huang, W., Chua, S. S., Wei, P., and Moore, D. D. (2002) Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR, Science 298, 422-424.
13. Bergman, K., Muller, L., and Teigen, S. W. (1996) Series: The genotoxicity and carcinogenicity of paracetamol: a regulatory (re)-view, Mutat. Res. 349, 263-288.
14. Bae, M. A., Pie, J. E., and Song, B. J. (2001) Acetaminophen induces apoptosis of C6 glioma cells by activating the c-Jun NH-(2)-terminal protein kinase-related cell death pathway, Mol. Pharmacol. 60, 847-856.
15. Dybing, E., Holme, J. A., Gordon, W. P., Soderlund, E. J., Dahlin, D. C., and Nelson, S. D. (1984) Genotoxicity studies with paracetamol, Mutat. Res. 138, 21-32.
16. Mitchell, J. R., Thorgeirsson, S. S., Potter, W. Z., Jollow, D. J., and Keiser, H. (1974) Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy, Clin. Pharmacol. Ther. 16, 676-684.
17. Albano, E., Rundgren, M., Harvison, P. J., Nelson, S. D., and Moldeus, P. (1985) Mechanisms of N-acetyl-p-benzoquinone imine cytotoxicity, Mol. Pharmacol. 28, 306-311.
18. Wang, J. C. (1996) DNA Topoisomerases, Annu. Rev. Biochem. 65, 635-692.
19. Berger, J. M., Gamblin, S. J., Harrison, S. C., and Wang, J. C. (1996) Structure and mechanism of DNA topoisomerase II, Nature 379, 225-232.
20. Burden, D. A., and Osheroff, N. (1998) Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme, Biochim. Biophys. Acta 1400, 139-154.
21. Nitiss, J. L. (1998) Investigating the biological functions of DNA topoisomerases in eukaryotic cells, Biochim. Biophys. Acta 1400, 63-81.
22. Wang, J. C. (1998) Moving one DNA double helix through another by a type II DNA topoismerase: the story of a simple molecular machine, Q. Rev. Biophys. 31, 107-144.
23. Fortune, J. M., and Osheroff, N. (2000) Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice, Prog. Nucleic Acid Res. Mol. Biol. 64, 221-253.
24. Wilstermann, A. M., and Osheroff, N. (2003) Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes, Curr. Top. Med. Chem. 3, 321-338.
25. Wang, J. C. (2002) Cellular roles of DNA topoisomerases: a molecular perspective, Nat. Rev. Mol. Cell. Biol. 3, 430-440.
26. Goto, T., and Wang, J. C. (1984) Yeast DNA topoisomerase II is encoded by a single-copy, essential gene, Cell 36, 1073-1080.
27. Voelkel-Meiman, K., DiNardo, S., and Sternglanz, R. (1986) Molecular cloning and genetic mapping of the DNA topoisomerase II gene of Saccharomyces cerevisiae, Gene 42, 193-199.
28. Uemura, T., Morikawa, K., and Yanagida, M. (1986) The nucleotide sequence of the fission yeast DNA topoisomerase II gene: structural and functional relationships to other DNA topoisomerases, EMBO J. 5, 2355-2361.
29. Nolan, J. M., Lee, M. P., Wyckoff, E., and Hsieh, T. S. (1986) Isolation and characterization of the gene encoding Drosophila DNA topoisomerase II, Proc. Natl. Acad. Sci. U.S.A. 83, 3664-3668.
30. Drake, F. H., Zimmerman, J. P., McCabe, F. L., Bartus, H. F., Per, S. R., Sullivan, D. M., Ross, W. E., Mattern, M. R., Johnson, R. K., Crooke, S. T., and Mirabelli, C. K. (1987) Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme, J. Biol. Chem. 262, 16739-16747.
31. Jenkins, J. R., Ayton, P., Jones, T., Davies, S. L., Simmons, D. L., Harris, A. L., Sheer, D., and Hickson, I. D. (1992) Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24, Nucleic Acids Res. 20, 5587-5592.
32. Tan, K. B., Dorman, T. E., Falls, K. M., Chung, T. D., Mirabelli, C. K., Crooke, S. T., and Mao, J. (1992) Topoisomerase II alpha and topoisomerase II beta genes: characterization and mapping to human chromosomes 17 and 3, respectively, Cancer Res. 52, 231-234.
33. Austin, C. A., and Marsh, K. L. (1998) Eukaryotic DNA topoisomerase Ilbeta, BioEssays 20, 215-226.
34. Heck, M. M., and Earnshaw, W. C. (1986) Topoisomerase II: A specific marker for cell proliferation, J. Cell Biol. 103, 2569-2581.
35. Heck, M. M., Hittelman, W. N., and Earnshaw, W. C. (1988) Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle, Proc. Natl. Acad. Sci. U.S.A. 85, 1086-1090.
36. Isaacs, R. J., Davies, S. L., Sandri, M. I., Redwood, C., Wells, N. J., and Hickson, I. D. (1998) Physiological regulation of eukaryotic topoisomerase II, Biochim. Biophys. Acta 1400, 121-137.
37. Grue, P., Grasser, A., Sehested, M., Jensen, P. B., Uhse, A., Straub, T., Ness, W., and Boege, F. (1998) Essential mitotic functions of DNA topoisomerase IIα are not adopted by topoisomerase IIβ in human H69 cells, J. Biol. Chem. 273, 33660-33666.
38. Wang, J. C. (2002) Cellular roles of DNA topoisomerases: a molecular perspective, Nat. Rev. Mol. Cell. Biol. 3, 430-440.
39. Sander, M., and Hsieh, T. (1983) Double strand DNA cleavage by type II DNA topoisomerase from Drosophila melanogaster, J. Biol. Chem. 258, 8421-8428.
40. Liu, L. F., Rowe, T. C., Yang, L., Tewey, K. M., and Chen, G. L. (1983) Cleavage of DNA by mammalian DNA topoisomerase II, J. Biol. Chem. 258, 15365-15370.
41. Zechiedrich, E. L., Christiansen, K., Andersen, A. H., Westergaard, O., and Osheroff, N. (1989) Double-stranded DNA cleavage/religation reaction of eukaryotic topoisomerase II: evidence for a nicked DNA intermediate, Biochemistry 28, 6229-6236.
42. Kaufmann, S. H. (1998) Cell death induced by topoisomerase-targeted drugs: more questions than answers, Biochim. Biophys. Acta 1400, 195-211.
43. Felix, C. A. (1998) Secondary leukemias induced by topoisomerase-targeted drugs, Biochim. Biophys. Acta 1400, 233-255.
44. Rowley, J. D. (1998) The critical role of chromosome translocations in human leukemias, Annu. Rev. Genet. 32, 495-519.
45. Kaufmann, S. H., Gore, S. D., Miller, C. B., Jones, R. J., Zwelling, L. A., Schneider, E., Burke, P. J., and Karp, J. E. (1998) Topoisomerase II and the response to antileukemic therapy, Leuk. Lymphoma 29, 217-237.
46. Sordet, O., Khan, Q. A., Kohn, K. W., and Pommier, Y. (2003) Apoptosis induced by topoisomerase inhibitors, Curr. Med. Chem. Anti-Cancer Agents 3, 271-290.
47. Pommier, Y. (1997) in Cancer Drug Discovery and Development (Teicher, B. A., Ed.) pp 153-174, Humana Press, Totowa, NJ.
48. Hande, K. R. (1998) Clinical applications of anticancer drugs targeted to topoisomerase II, Biochim. Biophys. Acta 1400, 173-184.
49. Li, T. K., and Liu, L. F. (2001) Tumor cell death induced by topoisomerase-targeting drugs, Annu. Rev. Pharmacol. Toxicol. 41, 53-77.
50. Toonen, T. R., and Hande, K. R. (2001) Topoisomerase II inhibitors, Cancer Chemother. Biol. Response Modif. 19, 129-147.
51. Walker, J. V., and Nitiss, J. L. (2002) DNA topoisomerase II as a target for cancer chemotherapy, Cancer Invest. 20, 570-589.
52. Kreuzer, K. N., and Cozzarelli, N. R. (1979) Escherichia coli mutants thermosensitive for deoxyribonucleic acid gyrase subunit A: effects on deoxyribonucleic acid replication, transcription, and bacteriophage growth, J. Bacteriol. 140, 424-435.
53. Wang, H., Mao, Y., Chen, A. Y., Zhou, N., LaVoie, E. J., and Liu, L. F. (2001) Stimulation of topoisomerase II-mediated DNA damage via a mechanism involving protein thiolation, Biochemistry 40, 3316-3323.
54. Zhou, N., Xiao, H., Li, T. K., Nur, E. K. A., and Liu, L. F. (2003) DNA damage-mediated apoptosis induced by selenium compounds, J. Biol. Chem. 278, 29532-29537.
55. Worland, S. T., and Wang, J. C. (1989) Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae, J. Biol. Chem. 264, 4412-4416.
56. Elsea, S. H., Hsiung, Y., Nitiss, J. L., and Osheroff, N. (1995) A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine, J. Biol. Chem. 270, 1913-1920.
57. Kingma, P. S., Greider, C. A., and Osheroff, N. (1997) Spontaneous DNA lesions poison human topoisomerase IIα and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints, Biochemistry 36, 5934-5939.
58. Fortune, J. M., and Osheroff, N. (1998) Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage, J. Biol. Chem. 273, 17643-17650.
59. O'Reilly, E. K., and Kreuzer, K. N. (2002) A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents, Biochemistry 41, 7989-7997.
60. Byl, J. A., Fortune, J. M., Burden, D. A., Nitiss, J. L., Utsugi, T., Yamada, Y., and Osheroff, N. (1999) DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement, Biochemistry 38, 15573-15579.
61. Subramanian, D., Kraut, E., Staubus, A., Young, D. C., and Muller, M. T. (1995) Analysis of topoisomerase I/DNA complexes in patients administered topotecan, Cancer Res. 55, 2097-2103.
62. Byl, J. A., Cline, S. D., Utsugi, T., Kobunai, T., Yamada, Y., and Osheroff, N. (2001) DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action, Biochemistry 40, 712-718.
63. Dargan, P. I., and Jones, A. L. (2002) Acetaminophen poisoning: an update for the intensivist, Crit. Care 6, 108-110.
64. Osheroff, N. (1989) Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide, Biochemistry 28, 6157-6160.
65. Robinson, M. J., and Osheroff, N. (1991) Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II, Biochemistry 30, 1807-1813.
66. Robinson, M. J., Martin, B. A., Gootz, T. D., McGuirk, P. R., Moynihan, M., Sutcliffe, J. A., and Osheroff, N. (1991) Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage, J. Biol. Chem. 266, 14585-14592.
67. Robinson, M. J., Corbett, A. H., and Osheroff, N. (1993) Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II, Biochemistry 32, 3638-3643.
68. Elsea, S. H., McGuirk, P. R., Gootz, T. D., Moynihan, M., and Osheroff, N. (1993) Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential, Antimicrob. Agents Chemother. 37, 2179-2186.
69. Corbett, A. H., Hong, D., and Osheroff, N. (1993) Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme, J. Biol. Chem. 268, 14394-14398.
70. Hammonds, T. R., and Maxwell, A. (1997) The DNA dependence of the ATPase activity of human DNA topoisomerase IIα, J. Biol. Chem. 272, 32696-32703.
71. Morris, S. K., and LIndsley, J. E. (1999) Yeast topoisomerase II is inhibited by etoposide after hydrolyzing the first ATP and before releasing the second ADP, J. Biol. Chem. 274, 30690-30696.
72. Padget, K., Pearson, A. D., and Austin, C. A. (2000) Quantitation of DNA topoisomerase IIα and β in human leukaemia cells by immunoblotting, Leukemia 14, 1997-2005.
73. Barrett, J. F., Gootz, T. D., McGuirk, P. R., Farrell, C. A., and Sokolowski, S. A. (1989) Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents, Antimicrob. Agents Chemother. 33, 1697-1703.
74. Elsea, S. H., Westergaard, M., Burden, D. A., Lommenick, J. P., and Osheroff, N. (1997) Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs, Biochemistry 36, 2919-2924.
75. Kingma, P. S., Corbett, A. H., Burcham, P. C., Marnett, L. J., and Osheroff, N. (1995) Abasic sites stimulate double-stranded DNA cleavage mediated by topoisomerase II: anticancer drugs mimic endogenous DNA lesions., J. Biol. Chem. 270, 21441-21444.
76. Kingma, P. S., and Osheroff, N. (1997) Spontaneous DNA damage stimulates topoisomerase II-mediated DNA cleavage, J. Biol. Chem. 272, 7488-7493.
77. Kingma, P. S., and Osheroff, N. (1997) Apurinic sites are position-specific topoisomerase II poisons, J. Biol. Chem. 272, 1148-1155.
78. Kingma, P. S., and Osheroff, N. (1998) Topoisomerase II-mediated DNA cleavage and religation in the absence of base pairing: abasic lesions as a tool to dissect enzyme mechanism, J. Biol. Chem. 273, 17999-18002.
79. Kingma, P. S., and Osheroff, N. (1998) The response of eukaryotic topoisomerases to DNA damage, Biochim. Biophys. Acta 1400, 223-232.
80. Sabourin, M., and Osheroff, N. (2000) Sensitivity of human type II topoisomerases to DNA damage: stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions, Nucleic Acids Res. 28, 1947-1954.
81. Wilstermann, A. M., and Osheroff, N. (2001) Base excision repair intermediates as topoisomerase II poisons, J. Biol. Chem. 276, 46290-46296.